Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model

Esteban C. Nannini, Suresh R. Pai, Kavindra V. Singh, Barbara E. Murray

Research output: Contribution to journalArticlepeer-review

Abstract

A novel glycylcycline agent, tigecycline (GAR-936), was evaluated in vivo in the mouse model of peritonitis against three Enterococcus faecalis and four Enterococcus faecium isolates with different susceptibilities to vancomycin and tetracyclines, all of which were inhibited by ≤0.125 μg of tigecycline/ml. Using a single subcutaneous dose, tigecycline displayed a protective effect (50% protective dose, ≤5.7 mg/kg of body weight) against all strains tested, including two with Tn925 (from the Tn916 family), which contains the Tet(M) tetracycline resistance determinant, as well as VanA and VanB strains. As expected, tetracycline and minocycline were ineffective against the isolates carrying Tn925.

Original languageEnglish (US)
Pages (from-to)529-532
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume47
Issue number2
DOIs
StatePublished - Feb 1 2003

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model'. Together they form a unique fingerprint.

Cite this